WHO ICTRP trial
A Randomized, Double-Blind, Active-Controlled Study of Patients With…
PER-022-09 · Registro Peruano de Ensayos Clínicos (REPEC) · Not Recruiting
Key facts
| Trial ID | PER-022-09 |
|---|---|
| Public title | A Randomized, Double-Blind, Active-Controlled Study of Patients With Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled With Simvastatin or Atorvastatin: Comparison of Switching to Combination Tablet Ezetimibe/Simvastatin Versus Switching to Rosuvastatin or Doubling the Statin Dose |
| Scientific title | A Randomized, Double-Blind, Active-Controlled Study of Patients With Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled With Simvastatin or Atorvastatin: Comparison of Switching to Combination Tablet Ezetimibe/Simvastatin Versus Switching to Rosuvastatin or Doubling the Statin… |
| Primary sponsor | MERCK SHARP & DOHME PERU S.R.L., |
| Registry | Registro Peruano de Ensayos Clínicos (REPEC) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | III |
| Countries | Germany;Austria;Bulgaria;Latovia;Croatia;Estonia;Greece;Hungary;Egypt;Italy;Lithuania;Portugal;Chile;Costa Rica;Peru;United States |
| Conditions | -E78 Disorders of lipoprotein metabolism and other lipidaemias Disorders of lipoprotein metabolism and other lipidaemias;E78 ;Disorders of lipoprotein metabolism and other lipidaemias |
| Interventions | Group name:Group 1 Type of group;1 N° of participants:320 Intervention(s) description:Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks. All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets… |
| Registration date | Aug 5, 2009 |
| Target size | 50 |
| Secondary IDs | NCT00862251 |
| Registry page | ins.gob.pe |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: